Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q3 FY26 Earnings Presentation
25 slides from Balaxi Pharmaceuticals's earnings presentation, Jan 29, 2026
Slide 1: Cover letter to NSE on investor presentation
Date:29.01.2026 To, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations an
Slide 2: Balaxi Pharmaceuticals Limited Investor Presentation
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
' Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actua
Slide 4: Corporate Snapshot, Financial Highlights, Strategic Roadmap
04 Corporate Snapshot 17 Financial Highlights 23 Strategic Roadmap Balaxi
Slide 5: Balaxi company snapshot
Branded IPR-based pharma company Frontier markets leadership in Latin America and Africa Vast portfolio across diverse therapeutic areas Asset light structure for expansion in semi-regulated markets Balaxi
Slide 6: Expansion, supply chain and distribution transformation
Expansion initiated: Ecuador, Chile (Latin America) 948 product registrations in Seven countries 200+ registrations submitted or in the pipeline Established the Company’s first Supply Chain pharmaceutical formulation facility in Hyderabad Successful process being replicated in other Distribution fro
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology = Focus on countries with high-potential economic growth framework = |dentify non-English speaking countries with similar characteristics = Low competitive intensity and potential to establish top-2 position = On-ground feedback mechanism allows deep
Slide 8: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” Marketing and Market Research ’ Product Product Manufacturing ’ Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi has moved its business model from ‘Asset Light’ to ‘Asset Ri
Slide 9: Investment in Manufacturing Facilities
; . . epegs oo . ' Investment in Manufacturing Facilities Lo N N . L] L] L] . ° . L] Company'’s first pharmaceutical formulation manufacturing unit ° General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of
Slide 10: Glimpse of Company's first Formulation Facility
. Glimpse of Company’s first Formulation Facility: -~ Balaxi
Slide 11: Glimpse of Company's first Formulation Facility
. Glimpse of Company’s first Formulation Facility: _ | all "H — Balaxi
Slide 12: Glimpse of Company's first Formulation Facility
S — Glimpse of Company’s first Formulation Facility:
Slide 13: Existing and targeted markets
Portugal . ‘ Existing Market Dominican Republic @ Targeted Expansion Guatemala ) Honduras . Product Sourcing Regions El Salvador Ecuador Balaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of S 6 billion Tfi aiaxi 12
Slide 14: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 15: Existing subsidiary companies
Balaxi Global FZCO, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Nicaragua SRL (WOS) S.A (WOS) (WOS) (Wos) (WOS) (WOS) Existing subsidiary companies Balaxi 14
Slide 16: Board of Directors
Ashish Maheshwari /Minoshi Maheshwari /Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi experience, manages First Water
Slide 17: Dynamic Leadership Team
Dynamic Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associat
Slide 18: Financial Highlights
FINANCIAL HIGHLIGHTS Balaxi
Slide 19: Q3 FY26 management commentary
“Q3 FY26 delivered a strong sequential recovery, with revenue at X72.54 crore, reflecting a marginal 1% YoY decline from X73.29 crore in Q3 FY25, while recording a 29% QoQ growth over X56.18 crore in Q2 FY26. The quarter was impacted by challenges in the Angola market, largely due to an extended wor
Slide 20: Quarterly Financial Performance - Consolidated
“Quarterly Financial Performance - Consolidated Particulars (InR crore) Q3 FY25 Revenue 73.29 29.45 Gross Margin % 40.2% EBITDA 7.93 EBITDA Margin 10.8% Profit After Tax 5.36 PAT Margin % 7.3% Earning Per Share (in Rs.) 0.97 Balaxi
Slide 21: Pharma Product Mix — Q3 FY26
Pharma Product Mix — Q3 FY26 Geographies Products u Africa* = Branded u LATM** = Generics Dosage Forms Therapeutic Areas m Tablets m Antibiotics = Injectables ELES = Analgesic = Liquids = Anti-malaria = Capsules = Others m Others 9 Balaxi *Africa: Angola *LATM - Guatemala, Dominican Republic, Hondur
Slide 22: Annual financial performance
Particulars (INR crore) . Revenue Gross Margin EBITDA EBITDA Margin % Profit After Tax PAT Margin % Earnings Per Share (INR) *NOTE: During the 1t quarter of the FY 24, the Angolan currency Kwanza underwent an unprecedented sharp depreciation, falling from 511.50 AOA/USD to 832.5 AOA/USD. Since the c
Slide 23: Pharma Product Mix — FY25
Pharma Product Mix — FY25 Geographies Products m Africa* = Branded u LATAM** = Generics Therapeutic Areas P Dosage Forms M m Tablets m Antibiotics = Injectables = Analgesic = Liquids = Anti-malaria = Capsules = Others m Others Balax’ *Africa: Angola and Central African Republic *LATAM — Guatemala, D
Slide 24: Core Strategy: Enter, Expand & Excel
' Core Strategy: Enter, Expand & Excel s Balaxi in 2020: Business Consolidation .. = Presence across Angola, Guatemala and Dominican Republic = Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-24: Expansion into New Geographies = Aim
Slide 25: Thank You
Our Offerings o Balaxi Pharmaceuticals Limited Others Anti-Emetic @ Plot No. 409, H.No. 8-2-293, 3rd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 @ Sunny Purohit i © +91-40-2355-5300 e o o o B sunny@balaxi.com N ® www.balaxipharma.in . : : . ® NSE BALA
Balaxi Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix